Loading
DRD5 (Dopamine receptor D5) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.
G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signalling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. Dopamine receptors can be classified in two categories: (1) DRD5 (together with DRD1) is a D1-type receptor and is coupled to G(s) G proteins, mediating activation of adenylate cyclase activity, while D2-type receptors (DRD2, DRD3 and DRD4) are coupled to G(i)/G(o) G proteins and promote inhibition of adenylate cyclase activity.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Dordaviprone.
In plain words · DRD5 (Dopamine receptor D5) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.
DRD5 (Dopamine receptor D5) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.
G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure.
No product in this corpus aims at DRD5 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA DRD5: RNA group enriched (brain 3 nTPM, lymphoid tissue 1 nTPM, stomach 1 4 nTPM); high antibody staining in 2 normal tissues. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Brain and spinal cord tumours (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas DRD5 tissue; Open Targets ENSG00000169676 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Sunahara R.K. et al, Nature, 1991, "Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1". Source.
Sources: HGNC HGNC:3026 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P21918 (protein name, function text, keywords and locations (REST API)); CIViC gene DRD5 (1 evidence items, 0 assertions, 1 variants; diseases: Glioblastoma (GraphQL API, CC0))
G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signalling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. Dopamine receptors can be classified in two categories: (1) DRD5 (together with DRD1) is a D1-type receptor and is coupled to G(s) G proteins, mediating activation of adenylate cyclase activity, while D2-type receptors (DRD2, DRD3 and DRD4) are coupled to G(i)/G(o) G proteins and promote inhibition of adenylate cyclase activity. D1- and D2-type dopamine receptors have antagonistic effects, particularly in the brain's striatum, where they govern voluntary movement and reward: D1-type receptors generally stimulate neural activity and promotes action, while D2-type receptors tend to inhibit neural activity and suppress movement. DRD5 acts as a key regulator of blood pressure: negatively regulates the renin-angiotensin system (RAS), thereby reducing renal sodium absorption by the kidney. Location: Cell membrane (UniProt). Locus 4p16.1 (HGNC).
RNA: group enriched (brain 3 nTPM, lymphoid tissue 1 nTPM, stomach 1 4 nTPM), detected in some normal tissues.
No cancer stained high; medium in pancreatic cancer.
HPA DRD5 tissue · HPA DRD5 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"DRD5" OR ABSTRACT:"DRD5" OR TITLE:"dopamine receptor D5" OR ABSTRACT:"dopamine receptor D5" OR TITLE:"Dopamine receptor D5" OR ABSTRACT:"Dopamine receptor D5" OR TITLE:"DRD1B" OR ABSTRACT:"DRD1B" OR TITLE:"DRD1L2" OR ABSTRACT:"DRD1L2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DRD5, not a curated reading list.